EuropaBio, the European Association for Bioindustries, today announces the finalists for 8th edition of the Most Innovative European Biotech SME Awards, which recognizes innovative biotech SMEs and the crucial role they play in answering some of society’s greatest challenges.
Twenty-five small and medium biotech companies contended for this year’s awards, with five of them shortlisted by the Jury to compete across three categories: healthcare, industrial and agricultural biotechnology. They will be showcased during a pitching session, followed by an awards ceremony hosted by Awards Jury Member and MEP Paul Rubig at the European Parliament in Brussels, Belgium on November 22.
The five shortlisted SMEs are:
Nightingale Health, a Finnish biotechnology company addressing chronic diseases with a proprietary blood analysis platform that can improve risk prediction of, among others, cardiovascular diseases and diabetes.
NovaBiotics, a UK-based clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
Carbios, a French green chemistry company focused on discovering and developing enzymatic bioprocesses to reinvent the lifecycle of plastics.
Numaferm, a German spin-off company from the Institute of Biochemistry of the Heinrich-Heine-University in Düsseldorf that has developed a reliable, cost-efficient technology to manufacture peptides based on well-designed microorganisms that convert simple nutrients to peptides.
Agricultural/ “Green Biotech” Category
Iden Biotechnology, a Spanish company developing biotech products and integrated solutions for crop yield and quality enhancement, including agrobiological products (e.g. plant biostimulants and biopesticides), and more productive crop varieties.
Visit the awards website to read more about the awards, the jury and the rules.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.